Emicizumab is a bispecific antibody that targets Factors IXa and X. It mimics Factor VIIIa cofactor activity and is used for prophylaxis in patients with hemophilia A. Its presence can interfere with aPTT-based assays.
To read more or access our algorithms and calculators, please log in or register.
